BioSpace News Archive

The value delivered is significant as it improves efficiencies.

Turning Point Therapeutics, Inc., a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in a question and answer session at the 38th annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 15, 2020.

Acquisition Strengthens Development of Personalized Closed Loop Technology for Diabetes Management

In 2018, the FDA granted orphan drug designation to ARMGO for ARM210 as a potential treatment for patients with RYR1-RM.

Through the addition of The Johns Hopkins Hospital in Baltimore, Carrum continues aggressive expansion of its network

FemmePharma today announced it has received clearance from the US Food & Drug Administration under Section 510(k) of the Food, Drug and Cosmetic Act to manufacture and bring to market its SatisfaiteTM delivery system for the relief of vaginal symptoms of menopause affecting more than one in three women in the US alone.

NeoMed, an enteral feeding and medication delivery solution leader, announced today it has received intellectual property protection for its ENFit® Low Dose Tip Syringe in the form of US Patent No. 10,420,709, entitled “Dosing Control Coupling For Enteral Fluid Transfer.”

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401

Chubb has introduced a new fidelity insurance solution, the Financial Institution Bond for Asset Managers, to address the unique range of risks faced by today’s asset managers.

According to Coherent Market Insights, the global electronic hearing protection devices market is expected to be valued at US$ 441.2 million in 2019, and is projected to exhibit a CAGR of 8.0% over the forecast period.